Carfilzomib-induced atypical hemolytic uremic syndrome in a patient with heterozygous, CFHR3/CFHR1 deletion treated with eculizumab

Thrombotic microangiopathy (TMA) encompasses a collection of syndromes characterized by endothelial injury, microangiopathic hemolytic anemia (MAHA) and organ failure. Atypical hemolytic uremic syndrome (aHUS) is a subtype of TMA related to excessive alternative complement pathway activation and typically presents with acute renal failure in addition to the aforementioned features of TMA. Patients may also present with cardiovascular, respiratory, or neurologic symptoms in addition to multiorgan dysfunction.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 14, 2021 Category: Hematology Authors: Craig W. Freyer, Erin M. Bange, Sarah Skuli, Miles Hsu, John Lin, Adam Cuker, Adam D. Cohen, Alfred Garfall Tags: Clinical Lymphoma, Myeloma and Leukemia Source Type: research